SPOTLIGHT -
Merck to acquire EyeBio for upfront payment of $1.3 billion
Claris Bio's journey toward treating neurotrophic keratitis
AI, big data, and personalized medicine: Scientists reveal playbook designed to revolutionize healthcare
(EyePod) From idea to impact: Navigating ophthalmic innovation
Opthea completes enrollment in pivotal Phase 3 clinical program with sozinibercept in wet AMD
Latest FDA biosimilar approvals ushering in more treatment options